NCT07879898Active, not recruiting
Radiotherapy Target Volume in Locally Advanced Esophageal Squamous Cell Carcinoma in the Immunotherapy Era
Efficacy and Safety of Different Radiotherapy Target Volume Extents in Locally Advanced Esophageal Squamous Cell Carcinoma in the Immunotherapy Era: A Real-World Cohort Study
Source: ClinicalTrials.gov · Last updated 19 Oct 2026
Brief summary (registry, in English)
This retrospective real-world cohort study will evaluate the efficacy and safety of different radiotherapy target volume extents in patients with locally advanced esophageal squamous cell carcinoma. Patients who previously received definitive or preoperative radiotherapy, with systemic treatment consisting of concurrent chemoradiotherapy with or without immunotherapy, will be identified from existing medical records. The study will not assign or modify any treatment. Patients will be classified according to the radiotherapy target volume actually used in clinical practice, including the longitudinal gross tumor volume-to-clinical target volume (GTV-CTV) margin and the extent of regional lymph node irradiation. The study will compare locoregional recurrence-free survival, recurrence patterns, overall survival, progression-free or disease-free survival, treatment completion, treatment-related toxicity, lymphocyte reduction, and postoperative outcomes among different target volume strategies. The aim is to provide real-world evidence to support individualized radiotherapy target volume selection in locally advanced esophageal squamous cell carcinoma.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 500 (estimated)
- First submitted
- 29 Sept 2026
- Start date
- 23 Jan 2018
- Primary completion date
- 30 Jun 2030
- Lead sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Diseases
- Gastric and esophageal cancer
- NCT number
- NCT07879898
What you commit to
- Study type: Observational
- Planned participants: 500
- From 23 Jan 2018 to the primary completion date, 30 Jun 2030
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous thoracic radiotherapy that could substantially affect current target volume design, dosimetric assessment, or outcome evaluation.
- Missing original radiotherapy plan or DICOM-RT data, preventing determination of the GTV-CTV longitudinal margin, regional lymph node irradiation extent, or key dosimetric parameters.
Other illness
- Distant metastasis, malignant pleural or peritoneal effusion before treatment, or radiotherapy given with a clearly palliative intent.
- Other active malignancies that could substantially affect survival or recurrence outcomes.
Other
- Severe missing clinical, pathological, or follow-up data preventing determination of the primary exposure or major outcomes.
- Duplicate cases; only the first eligible treatment record will be included.
Who the study is looking for
- Age ≥18 years at the start of treatment, regardless of sex.
- Histologically or cytologically confirmed esophageal squamous cell carcinoma.
- Clinical stage cT2-4aN0-3M0 and received definitive radiotherapy or preoperative radiotherapy, with systemic treatment consisting of concurrent chemoradiotherapy with or without immunotherapy.
- Received modern precision radiotherapy, including IMRT, VMAT, TOMO, or proton therapy, with the original radiotherapy plan, target structures, and dose distribution available for review.
- Contrast-enhanced CT available before treatment for staging and target volume review; endoscopy, EUS, PET/CT, or MRI may also be used when available.
- Major baseline characteristics, treatment information, and at least one efficacy or safety assessment available in the medical record; this requirement does not apply to patients who died during treatment.
- Treatment occurred within the predefined study period and met the data-use conditions approved by the ethics committee.
Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Coordinator of this site? Confirm its status | Beijing | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.